secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028761
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply
--------------------------------------------------------------------------------

- Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.
- Adjusted EBITDA $22.7M (+$1.3M YoY); Non-GAAP EPS $0.08, down from $0.19 prior year.
- Full-year 2022 guidance lowered: net sales $527-532M, Adj. EBITDA $75-79M, Non-GAAP EPS $0.20-0.25.
- Debt increased to $424.4M from $357.7M at Dec 2021; cash $34.4M.
- CEO highlights recent CartiHeal acquisition to enter large cartilage replacement market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/bvs-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer